Where does Biolase, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Biolase, Inc. ranks #9,448 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Biolase, Inc. hold?

Biolase, Inc. holds 33 US utility patents granted between 2015 and 2024, spanning 13 technology areas.

What is Biolase, Inc.'s Innovation Score?

Biolase, Inc. has an Innovation Score of 39.9 out of 100 (top 37% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Biolase, Inc. focus on?

Biolase, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 16 patents, ranking #1,103 of 7,127 assignees active in that subclass. Grants appear in 13 CPC subclasses total.

Is Biolase, Inc.'s patent grant rate increasing or decreasing?

Biolase, Inc.'s recent grant velocity is +6% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Biolase, Inc.'s patents?

Biolase, Inc.'s patents average 15.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Biolase, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Biolase, Inc.

USPTO PatentsView assignee record - 33 granted patents across 13 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Biolase ranks #9,448 of 49,997 tracked US assignees by granted-patent volume, with 33 patents across 13 technology areas.

#9,448
of 49,997 US assignees by volume: Top 37%
by Innovation Score (39.9/100): 15.8
avg claims per patent: +6%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R9448 · US Corporation #9,448 · 33 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 33 grants
UPPER-Q #9,448/49,997
PHOTO-FINISH Beam Engineering…
CPC-FOCUS A61B · 13 areas
INNOV-THIN 39.9/100
CLAIMS-RICH 15.8 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +6% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Beam Engineering for Advanced Measurements Co. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Biolase’s 39.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.2 pts (31%) Velocity 5.5 pts (14%) Breadth 12.7 pts (32%) Claim depth 9.5 pts (24%)

Qualcomm Incorporated · highest

85
Biolase · this assignee

40
The University… · near

40
Weltrend Semiconductor · near

40
Pac Tech—Packaging · near

40
TriVascular · near

40
3D Lighting… · lowest

7

What this shows Biolase's Innovation Score is 39.9/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Biolase?

Each dot is one of Biolase’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Biolase’s own 15.8 claims/patent is ABOVE the 15.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Biolase vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Biolase's grants concentrate

Biolase, Inc. is a focused PatentsView assignee: 13 CPC subclasses with 48.5% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2018 (8 grants) versus a trough of 1 in 2022. By volume, Biolase sits between Btsr International S.P.A. and Bluestar Silicones France SAS.

Biolase's three-year grant acceleration

Biolase, Inc. shows 9 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Btsr Internationa…

33
Beam Engineering…

33
Biomedical Enterp…

33
Biocytogen Pharma…

33
Blaize

33
Blinker

33
Bluebeam

33
Bluestar Silicone…

33
Biolase ◀

33

What this shows Biolase holds 33 patents at rank #9,453, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Biolase

By rank, the assignees closest to #9,453 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Biolase's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Biolase, neither rank-band nor same-CPC leaders (those blocks stay above). In A61B (Diagnosis), Biolase ranks #1,103 of 7,127 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Weltrend Semiconductor Inc. 40 The University Court of the University of Aberdeen 40 Pac Tech—Packaging Technologies Gmbh 40 TriVascular, Inc. 40

Biolase's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Biolase, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	9.1%
2017	2	6.1%
2018	8	24.2%
2019	3	9.1%
2020	3	9.1%
2021	5	15.2%
2022	1	3.0%
2023	5	15.2%
2024	3	9.1%

Which technologies does Biolase, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 16

A61C - DENTISTRY; Apparatus OR Methods FOR Oral OR Dental Hygiene 14

G06F - Electric Digital Data Processing 12

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 12

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 6

C03C - Chemical Composition OF Glasses, Glazes OR Vitreous ENAMELS; Surface Treatment OF GLASS; Surface Treatment OF Fibres OR Filaments Made From Glass, Minerals OR SLAGS; Joining Glass TO Glass OR Other Materials 3

C23C - Coating Metallic MATERIAL; Coating Material With Metallic MATERIAL; Surface Treatment OF Metallic Material BY Diffusion Into THE Surface, BY Chemical Conversion OR SUBSTITUTION; Coating BY Vacuum Evaporation, BY Sputtering, BY ION Implantation OR BY Chemical Vapour Deposition, IN General 3

G02B - Optical Elements, Systems OR Apparatus 3

A61G - Transport, Personal Conveyances, OR Accommodation Specially Adapted FOR Patients OR Disabled Persons ; Operating Tables OR CHAIRS; Chairs FOR DENTISTRY; Funeral Devices 3

G06Q - Information AND Communication Technology [ICT] Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory PURPOSES; Systems OR Methods Specially Adapted FOR Administrative, Commercial, Financial, Managerial OR Supervisory Purposes, NOT Otherwise Provided FOR 1

B23K - Soldering OR UNSOLDERING; WELDING; Cladding OR Plating BY Soldering OR WELDING; Cutting BY Applying Heat Locally, e.g. Flame CUTTING; Working BY Laser Beam 1

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

H01S - Devices Using THE Process OF Light Amplification BY Stimulated Emission OF Radiation [LASER] TO Amplify OR Generate LIGHT; Devices Using Stimulated Emission OF Electromagnetic Radiation IN Wave Ranges Other Than Optical 1

Top 13 of 13 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Biolase, Inc.'s patent record in context - here's where to go next.

Biolase, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 48.5% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #9,448 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Biolase, Inc. against Btsr International S.P.A., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.